479 related articles for article (PubMed ID: 30483731)
1. Potential four‑miRNA signature associated with T stage and prognosis of patients with pancreatic ductal adenocarcinoma identified by co‑expression analysis.
You L; Wang J; Zhang F; Zhang J; Tao H; Zheng X; Hu Y
Mol Med Rep; 2019 Jan; 19(1):441-451. PubMed ID: 30483731
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel genes associated with a poor prognosis in pancreatic ductal adenocarcinoma via a bioinformatics analysis.
Zhou J; Hui X; Mao Y; Fan L
Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31311829
[TBL] [Abstract][Full Text] [Related]
3. Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis.
Giulietti M; Occhipinti G; Principato G; Piva F
Cell Oncol (Dordr); 2017 Apr; 40(2):181-192. PubMed ID: 28205147
[TBL] [Abstract][Full Text] [Related]
4. Bioinformatic Analysis Suggests That Three Hub Genes May Be a Vital Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma.
Chang X; Yang MF; Fan W; Wang LS; Yao J; Li ZS; Li DF
J Comput Biol; 2020 Nov; 27(11):1595-1609. PubMed ID: 32216644
[TBL] [Abstract][Full Text] [Related]
5. Identification of Key Prognostic Biomarker and Its Correlation with Immune Infiltrates in Pancreatic Ductal Adenocarcinoma.
Luan H; Zhang C; Zhang T; He Y; Su Y; Zhou L
Dis Markers; 2020; 2020():8825997. PubMed ID: 32934754
[TBL] [Abstract][Full Text] [Related]
6. Construction of a prognostic prediction system for pancreatic ductal adenocarcinoma to investigate the key prognostic genes.
Zheng B; Peng J; Mollayup A; Bakri A; Guo L; Zheng J; Xu H
Mol Med Rep; 2018 Jan; 17(1):216-224. PubMed ID: 29115420
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of Topoisomerase 2-Alpha Confers a Poor Prognosis in Pancreatic Adenocarcinoma Identified by Co-Expression Analysis.
Zhou Z; Liu S; Zhang M; Zhou R; Liu J; Chang Y; Zhao Q
Dig Dis Sci; 2017 Oct; 62(10):2790-2800. PubMed ID: 28815403
[TBL] [Abstract][Full Text] [Related]
8. Identification of hub genes and regulators associated with pancreatic ductal adenocarcinoma based on integrated gene expression profile analysis.
Shang M; Zhang L; Chen X; Zheng S
Discov Med; 2019 Sep; 28(153):159-172. PubMed ID: 31926587
[TBL] [Abstract][Full Text] [Related]
9. Identification of hub genes and construction of transcriptional regulatory network for the progression of colon adenocarcinoma hub genes and TF regulatory network of colon adenocarcinoma.
Wei S; Chen J; Huang Y; Sun Q; Wang H; Liang X; Hu Z; Li X
J Cell Physiol; 2020 Mar; 235(3):2037-2048. PubMed ID: 31612481
[TBL] [Abstract][Full Text] [Related]
10. A Network-Based Approach for Identification of Subtype-Specific Master Regulators in Pancreatic Ductal Adenocarcinoma.
Zhang Y; Zhu L; Wang X
Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32024063
[TBL] [Abstract][Full Text] [Related]
11. Weighted gene co-expression network analysis reveals key genes involved in pancreatic ductal adenocarcinoma development.
Giulietti M; Occhipinti G; Principato G; Piva F
Cell Oncol (Dordr); 2016 Aug; 39(4):379-88. PubMed ID: 27240826
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Blood Plasma MicroRNAs to Enable Identification of Patients with Pancreatic Ductal Adenocarcinoma Who Will Benefit from Surgical Resection.
Gablo N. A; Procházka V; Hlavsa J; Kiss I; Srovnal J; Kala Z; Slabý O
Klin Onkol; 2019; 32(Suppl 1):174-176. PubMed ID: 31064193
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance and prospective molecular mechanism of C‑C motif chemokine receptors in patients with early‑stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy.
Zhou X; Liao X; Wang X; Huang K; Yang C; Yu T; Liu J; Han C; Zhu G; Su H; Qin W; Han Q; Liu Z; Huang J; Gong Y; Ye X; Peng T
Oncol Rep; 2019 Nov; 42(5):1856-1868. PubMed ID: 31432181
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive meta-analysis of transcriptome data to identify signature genes associated with pancreatic ductal adenocarcinoma.
Kordshouli SO; Tahmasebi A; Moghadam A; Ramezani A; Niazi A
PLoS One; 2024; 19(2):e0289561. PubMed ID: 38324544
[TBL] [Abstract][Full Text] [Related]
15. Identification of significant prognostic risk markers for pancreatic ductal adenocarcinoma: a bioinformatic analysis.
Zhang Z; Sun W; Zeng Z; Lu Y
Acta Biochim Pol; 2022 Jun; 69(2):327-333. PubMed ID: 35675627
[TBL] [Abstract][Full Text] [Related]
16. Identification of a 5‑microRNA signature and hub miRNA‑mRNA interactions associated with pancreatic cancer.
Ma X; Tao R; Li L; Chen H; Liu Z; Bai J; Shuai X; Wu C; Tao K
Oncol Rep; 2019 Jan; 41(1):292-300. PubMed ID: 30365134
[TBL] [Abstract][Full Text] [Related]
17. Identification of key regulators of pancreatic cancer progression through multidimensional systems-level analysis.
Rajamani D; Bhasin MK
Genome Med; 2016 May; 8(1):38. PubMed ID: 27137215
[TBL] [Abstract][Full Text] [Related]
18. Gene signature and connectivity mapping to assist with drug prediction for pancreatic ductal adenocarcinoma.
Xiao Y; Zhang B; Cloyd JM; Xu G; Du S; Mao Y; Pawlik TM
Surg Oncol; 2022 Sep; 44():101849. PubMed ID: 36116415
[TBL] [Abstract][Full Text] [Related]
19. Serum level of co-expressed hub miRNAs as diagnostic and prognostic biomarkers for pancreatic ductal adenocarcinoma.
Su Q; Zhu EC; Qu YL; Wang DY; Qu WW; Zhang CG; Wu T; Gao ZH
J Cancer; 2018; 9(21):3991-3999. PubMed ID: 30410604
[No Abstract] [Full Text] [Related]
20. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
[Next] [New Search]
